AbCellera Biologics Inc.
NASDAQ:ABCLBiotechnology
-$0.02 today
- Market cap
- $3.42B
- Beta
- 1.20
- P/E (TTM)
- -11.4
- EPS (TTM)
- -$0.47
Volume 2.48M
Average 6.37M
Returns on capital
AbCellera Biologics Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-15.1%
avg -2.5%
ROIC
-13.8%
avg -5.0%
ROA
-10.8%
avg -0.9%
Analysis
ROA is currently the strongest return metric at -10.8% versus its period average of -0.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Carl Hansen | Chief Executive Officer, President & Chairperson | USD 931.15K | 51 | — | — |
Andrew Booth | Chief Financial Officer | USD 726.81K | 52 | 491.40K | 0.16% |
Tryn T. Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | USD 709.28K | 56 | — | — |
Veronique Lecault | Chief Technology Officer & Director | USD 681.65K | 41 | 5.20M | 1.70% |
Caitlin Webster CIPD | Director of Talent Development | — | — | — | — |
Marcie Thiessen | Senior Director of Finance & Accounting | — | — | — | — |
Adam Clarke | Senior Vice President of Discovery | — | — | — | — |
Andrew Knowles | Vice President of Operations | — | — | — | — |
Martin Hogan | Senior Director of Strategic Finance & IR | — | — | — | — |
Murray McCutcheon | Senior Vice President of Partnering | — | — | — | — |
Tiffany Chiu | Vice President of Communications | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 13, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
11
$3.47M
Sells
0
$0.00
Net Transaction Value
+$3.47M
Net buying
Most Active
Booth Andrew
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 13, 26Nov 13, 2026 | Booth Andrew Direct | Buy | $97.4K$97,438.00 |
| Nov 12, 26Nov 12, 2026 | Thermopylae Holdings Ltd. Direct | Buy | $698.9K$698,920.10 |
| Aug 24, 26Aug 24, 2026 | Hayden Michael R Indirect | Buy | $570.4K$570,442.32 |
| Aug 18, 26Aug 18, 2026 | Montalbano John S. Direct | Buy | $110.3K$110,300.00 |
| Aug 14, 26Aug 14, 2026 | Booth Andrew Direct | Buy | $383.9K$383,904.00 |
| Aug 12, 26Aug 12, 2026 | Hayden Michael R Indirect | Buy | $481K$481,033.19 |
| May 14, 26May 14, 2026 | Montalbano John S. Direct | Buy | $95.4K$95,400.00 |
| Feb 27, 26Feb 27, 2026 | Thermopylae Holdings Ltd. Direct | Buy | $130.7K$130,720.00 |
| Feb 27, 26Feb 27, 2026 | Booth Andrew Direct | Buy | $145.7K$145,692.00 |
| Feb 26, 26Feb 26, 2026 | Thermopylae Holdings Ltd. Direct | Buy | $580.3K$580,284.39 |
1–10 of 11
Summary
Insiders reported 11 buys worth $3.47M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $3.47M. Booth Andrew was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -46.3% | +10.6% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -46.3% over three years. Forward estimates point to Revenue at +10.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does AbCellera Biologics Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ABCL's management, answered from reported figures.
Who manages ABCL?
AbCellera Biologics Inc. (ABCL) lists 11 active executives. The top listed executive is Caitlin Webster CIPD, Director of Talent Development.
Are ABCL insiders buying or selling?
Recent insider activity shows net selling of $132.80M.
Continue the stock analysis
Jump to another research area for this company.